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and progression of chronic kidney disease?The historical association between hyperuricemia and kid- and secretion occur in the proximal tubule, and as a conse-
ney disease has been well-recognized from ancient times [1];
however, uric acid has been regarded as a marker rather than a
risk factor for the development of renal disease since a
decrease in glomerular ﬁltration rate (GFR) per se induces an
elevation in serum uric acid level despite compensatory
increases in urinary and gastrointestinal excretions of urate [2].
In the past decade, substantial data from epidemiological and
interventional studies has provided evidence that uric acid has
a causative role in the development and/or aggravation of
renal disease. In this issue of Kidney Research and Clinical
Practice, Kim et al. reported that where hyperuricemia was
already present at the time of diagnosis of immunoglobulin A
(IgA) nephropathy, this was associated with a higher rate of
renal progression [3]. Although this observational study did
not address whether uric acid per se caused an aggravation of
renal disease, hyperuricemia was an independent risk factor
for IgA nephropathy on multiple regression analysis adjusted
to age, gender, blood pressure, and proteinuria. It has been
reported already that uric acid at the time of kidney biopsy is
one of the independent risk factors determining renal prog-
nosis in IgA nephropathy [4]. Furthermore, treatment of
asymptomatic hyperuricemia with allopurinol delayed the
renal progression with a lesser increase in blood pressure in
patients with IgA nephropathy [5]. In this editorial, recent
understanding regarding the role of uric acid in chronic kidney
disease (CKD) will be highlighted, together with a review of
potential mechanisms by which renal disease might be
induced by uric acid, and a reappraisal of hyperuricemia as a
novel risk factor for renal progression in CKD.Causes of elevated serum uric acid level
Uric acid is a waste product resulting from the biological
oxidation of purines, including adenine and guanine – com-
ponents of deoxyribonucleic acid (DNA), ribonucleic acid
(RNA), and adenosine triphosphate (ATP). Approximately
two-thirds of total body urate is produced endogenously,
while the remaining third is accounted for by dietary purines
(present in fatty meat, organ meats, and seafood). The primary
site of excretion of uric acid is the kidney. The normal urinary
urate excretion is 250–750 mg per day, approximately 70% of
the daily urate production [2]. Although urate is freely ﬁltered
in the glomerulus, there is evidence that both reabsorption132/$ - see front matter & 2012. The Korean Society of Nephrology. P
nse (http://creativecommons.org/licenses/by-nc-nd/4.0/).
dx.doi.org/10.1016/j.krcp.2012.08.001quence the fractional urate excretion is only 8–10% in a
normal adult. After molecular identiﬁcation of urate transpor-
ter URAT01 (SLC22A12), several transmembrane molecules for
urate handling have been detected and are still under inves-
tigation. Serum uric acid level is determined by the balance
between generation and excretion of uric acid. Obesity, insulin
resistance, hypertension and use of diuretics have led to
decreased renal excretion of uric acid, and so they can be
confounding factors in determining the clinical signiﬁcance of
hyperuricemia in vascular and renal disease.Role of hyperuricemia in CKD: lessons from
epidemiological studies
Bellomo et al. demonstrated that a higher uric acid level
was associated with subsequent worsening of kidney func-
tion, and that this remained signiﬁcant after adjustment for
body mass index (BMI), blood pressure and proteinuria in a
prospective cohort of 900 healthy, normotensive adults [6]. A
recent study of more than 21,000 healthy participants also
revealed that increased uric acid independently increased the
risk for new-onset kidney disease [7]. In addition, the Athero-
sclerosis Risks in Communities and the Cardiovascular Health
Study collected data from 13,338 participants with intact
kidney function and analysis demonstrated that increased
serum uric acid level is a modest, independent risk factor for
incidental kidney disease in the general population [8]. Sev-
eral epidemiological studies performed in large populations
have shown that uric acid level was a major predictor for the
development of incident kidney disease [9–11].
An increased uric acid level is also associated with impaired
GFR in type 1 diabetes without proteinuria or prehypertension
[12]. However, other studies have shown conﬂicting results,
especially regarding the role of uric acid in the progression of
established kidney disease or in kidney transplant patients
[13,14]. Neither the Modiﬁcation of Diet in Renal Disease
Study nor the Mild to Moderate Kidney Disease Study con-
sidered uric acid to be a risk factor [15,16]. Therefore, it is still
controversial whether hyperuricemia can be considered a risk
factor for the progression of CKD. A recent study in middle-
aged and elderly Taiwanese people has shown that elevated
uric acid increased the risk of renal disease after an adjust-
ment for gender, BMI, cholesterol, triglycerides, blood pressureublished by Elsevier. This is an open access article under the CC BY-NC-
Duk-Hee Kang / Editorial130and blood sugar [17]. An interesting ﬁnding from this study
was that serum uric acid was independently associated with
estimated GFR (eGFR) only in stage 3 CKD, not in stages 4 or 5.Role of hyperuricemia in CKD: lessons from clinical
interventional studies
There have been a few observational and interventional
studies to examine the association of uric acid with renal
progression or the effect of uric acid lowering in the progres-
sion of IgA nephropathy [4,5,18]. In a recent randomized,
prospective study in 113 patients with a GFRo60 mL/minute,
allopurinol (100 mg/day) treatment resulted in a slowing
of the progression of renal disease after a mean time of
23.477.8 months [18]. No changes in blood pressure or in
albuminuria induced by allopurinol have been observed.
Interestingly, allopurinol treatment also reduces cardiovascu-
lar and hospitalization risk in these subjects. Although this
study may suggest a beneﬁcial effect of allopurinol in the
progression of renal disease, it is not certain whether the
effect is related to uric acid lowering or another effect of
allopurinol as an inhibitor of xanthine oxidase and/or as an
antioxidant. These results have to be conﬁrmed in larger
prospective trials and a comparison study undertaken to see
the effect of uricosuric agents.
Mechanism of uric acid induced renal disease
Most understandings about the mechanism of renal dis-
ease associated with uric acid emerged from the data in an
animal model of hyperuricemia using a uricase inhibitor.
Hyperuricemic rats showed preglomerular arterial disease,
renal inﬂammation, and hypertension via an activation of the
renin–angiotensin system (RAS) and COX-2 [19,20]. Once
thickening of the afferent arterioles and macrophage inﬁltra-
tion in vessel wall has been induced, preglomerular vasculo-
pathy may potentiate renal injury by causing ischemia to the
postglomerular circulation. The reduction in the lumen could
also provide a stimulus for the increase in the observed
expression of renin, and might also contribute to the devel-
opment of the marked hypertension in these rats, with an
ineffective autoregulation and increased transmission of sys-
temic pressures to the glomerulus. Uric acid also induced
the proinﬂammatory cytokine, monocyte chemoattractant
protein-1 (MCP-1), and the de novo expression of C-reactive
protein (CRP) in vascular cells, which was further shown to be
due to direct entry of uric acid into cells with activation of
mitogen activated protein (MAP) kinase and nuclear tran-
scription factor (NF-kB) [21,22]. In addition, uric acid can
become pro-oxidative under certain circumstances, in con-
trast to its natural antioxidant activity.
Consistent with experimental data, there has been some
evidence that uric acid is associated with endothelial dysfunc-
tion in patients with cardiovascular disease. Zoccali et al.
demonstrated an inverse relationship between uric acid and
acetylcholine-stimulated vasodilatation in patients with
untreated essential hypertension, even after adjusting for
differences in traditional cardiovascular risk factors [23].
Furthermore, allopurinol treatment yields potentially beneﬁcial
effects on peripheral or cerebrovascular endothelial function in
patients with chronic heart failure, type 2 diabetes and meta-
bolic syndrome [24,25].Conclusions
Evidence has been accumulating to support the hypothesis
that hyperuricemia may be a genuine risk factor for CKD
rather than an incidental ﬁnding related to declining glomer-
ular ﬁltration, and this is well grounded in recent epidemio-
logical, clinical, and experimental observations. Nonetheless,
there are still controversies regarding the causative role of
uric acid in the development or aggravation of CKD. Con-
sidering the worldwide epidemic of CKD, it is critical to
identify modiﬁable, novel risk factors for the disease and
treat them adequately. Uric acid may be one of the ignored
risk factors for CKD. In this sense, the clinical signiﬁcance of
hyperuricemia as a therapeutic target for CKD progression
needs to be investigated by performing large randomized
clinical trials to evaluate the effect of uric acid reduction on
renal progression, cardiovascular disease, and mortality in
CKD patients.Conﬂict of interest
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